Stock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects

Stock Track

02-21

GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.

Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.

Additionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1144662197"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1144662197\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1144662197?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-21 17:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144662197","market":"hk","top_or_hot":-1,"title":"Stock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects","media":"Stock Track","content":"<p>GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.</p>\n\n<p>Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.</p>\n\n<p>Additionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GRAIL, Inc. Soars 7.01% in Pre-Market on Optimistic Outlook for Cancer Screening and Robotaxi Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-21 17:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.</p>\n\n<p>Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.</p>\n\n<p>Additionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GRAL","symbol_name":"GRAIL, Inc.","start_time":0,"source_url":"","article_id":"1144662197","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144662197","pubTimestamp":1740130351,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"GRAIL, Inc.  saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.Analysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GRAL":"GRAIL, Inc."},"translate_title":"由于癌症筛查和机器人出租车前景乐观，GRAIL，Inc.盘前飙升7.01%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GRAL":1},"content_text":"GRAIL, Inc. (GRAL) saw its stock surge 7.01% in the pre-market trading session on Friday, driven by an optimistic outlook from analysts regarding the company's prospects in the cancer screening and early detection market, as well as its robotaxi project.\nAnalysts are bullish on GRAIL's potential in the liquid biopsy market, with its Galleri multi-cancer early detection test showing promising results in clinical trials. The company's recent partnerships with leading healthcare providers have fueled expectations for widespread adoption and revenue growth.\nAdditionally, GRAIL's Apollo Go robotaxi project is expected to break even in Wuhan in 2024 and achieve profitability in 2025 as the company expands its fleet in the city. These positive developments, along with GRAIL's strong Q4 2024 earnings, with a 26% increase in revenue and successful integration with Quest Diagnostics, have contributed to the market's optimism and the pre-market surge in the company's stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}